FDA Tobacco Products Scientific Advisory Shadow Panel

Monitoring the FDA's Regulation of Tobacco to Make Sure the Public's Health is Being Best Served

 
Home
Panel Members
Recommendations
Press Releases
Publications
Blog
Links
Contact Us
 
 
 
 
 

FDA Tobacco Products Scientific Advisory Shadow Panel


   

 

The FDA Tobacco Products Scientific Advisory Shadow Panel is a group of experts in the public health practice of tobacco control assembled by Dr. Michael Siegel and Dr. Alan Blum to monitor the FDA's Tobacco Products Scientific Advisory Committee and provide alternative recommendations to advise the FDA on matters related to the regulation of tobacco products.

The Shadow Panel follows the actions of the Tobacco Products Scientific Advisory Committee and the FDA in relation to the regulation of tobacco products and issues alternative or parallel reports and recommendations on the issues being considered by the Agency and its Advisory Committee.

The Shadow Panel reviews and evaluates safety, dependence, and health issues relating to tobacco products and provides appropriate advice, information and recommendations to the Commissioner of Food and Drugs.


The FDA Shadow Panel is needed in order to provide an alternative set of science-based recommendations that are free from corporate interests, political concerns, and financial conflicts of interest. The actual FDA Tobacco Products Scientific Advisory Committee is plagued by these problems, as it consists of three tobacco industry members and four of its scientific panel members have financial conflicts of interest with pharmaceutical companies.

 

The FDA Shadow Panel will issue periodic recommendations for tobacco policy, mirroring the Tobacco Products Scientific Advisory Committee's agenda and actions, but providing an alternative perspective that is evidence-based and free from political, corporate, or economic influence.


Eight of the nine Shadow Panel members have no financial conflicts of interest, either in terms of having taken tobacco money or having received funding from pharmaceutical companies. One Shadow Panel member has received honoraria from pharmaceutical companies for presentations or monograph development.

wordpress blog stats